Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29625190 | 0.99 | KMT2A (0.69) | KMT2AEPHX2TLR2FABP7FABP5 | |
| Hydrochloric Acid SCHEMBL6366017 | 0.99 | KMT2A (0.69) | KMT2AEPHX2TLR2FABP7FABP5 | |
| Bromide SCHEMBL15809739 | 0.99 | KMT2A (0.69) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL31135496 | 0.96 | KMT2A (0.73) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL5033236 | 0.96 | KMT2A (0.73) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL16297741 | 0.95 | KMT2A (0.65) | KMT2AEPHX2TLR2CA1CA2 | |
| SCHEMBL15160681 | 0.95 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL6036899 | 0.95 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL16379393 | 0.95 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| Bromide SCHEMBL15809407 | 0.95 | KMT2A (0.71) | KMT2AEPHX2TLR2FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109696-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | PRAZER THERAPEUTICS INC. (KR) | 2024-12-26 | — | — | US | disclosed |
| EP-4450490-A1 | NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION | Prazer Therapeutics Inc. (KR) | 2024-10-23 | — | — | EP | disclosed |
| US-12115224-B2 | Polypeptide conjugates for intracellular delivery of stapled peptides | OHIO STATE INNOVATION FOUNDATION (US) | 2024-10-15 | — | — | US | disclosed |
| US-12037336-B2 | Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) | Enterprise Therapeutics Limited (GB) | 2024-07-16 | — | — | US | disclosed |
| US-12037336-B2 | Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) | Enterprise Therapeutics Limited (GB) | 2024-07-16 | — | — | US | disclosed |
| US-20240067653-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2024-02-29 | — | — | US | disclosed |
| US-20240067653-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2024-02-29 | — | — | US | disclosed |
| CN-117567639-A | Polypeptide conjugates for intracellular delivery of binding peptides | 俄亥俄州国家创新基金会 | 2024-02-20 | — | — | CN | disclosed |
| CN-111447941-B | Polypeptide conjugates for intracellular delivery of binding peptides | 俄亥俄州国家创新基金会 | 2023-10-31 | — | — | CN | disclosed |
| US-8546533-B2 | Pipecolic linker and its use for chemistry on solid support | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2013-10-01 | — | — | US | disclosed |
| WO-2013116682-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20110152464-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | UNIVERSITE DE MONTPELLIER I (FR) | 2011-06-23 | — | — | US | disclosed |
| US-20110152464-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | UNIVERSITE DE MONTPELLIER I (FR) | 2011-06-23 | — | — | US | disclosed |
| EP-2321277-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | Centre National de la Recherche Scientifique - CNRS (FR) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010023295-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-03-04 | — | — | WO | disclosed |
| US-20080220536-A1 | Methods for Identifying Compounds that Modulate Enzymatic Activities by Employing Covalently Bonded Target-Extender Complexes with Ligand Candidates | ERIANSON DANIEL A | 2008-09-11 | — | — | US | disclosed |
| US-20080220536-A1 | Methods for Identifying Compounds that Modulate Enzymatic Activities by Employing Covalently Bonded Target-Extender Complexes with Ligand Candidates | ERIANSON DANIEL A | 2008-09-11 | — | — | US | disclosed |
| US-7214487-B2 | Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates | SUNESIS PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214487-B2 | Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates | SUNESIS PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | ADRM1, SUMO1, SUMO2 | KMT2A 2366/4885EPHX2 4171/4885TLR2 3672/4885 |
| US-12037336-B2 | Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) | SCNN1B, SCNN1A, SCNN1G | KMT2A 4545/4885EPHX2 3496/4885TLR2 4589/4885 |
| US-20240067653-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | KMT2A 4508/4885EPHX2 3856/4885TLR2 3988/4885 |
| US-20110152464-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | PRRC2C, VIP, PRRC2A | KMT2A 4248/4885EPHX2 175/4885TLR2 4645/4885 |
| US-12115224-B2 | Polypeptide conjugates for intracellular delivery of stapled peptides | VIP, IAPP, TAP1 | KMT2A 4716/4885EPHX2 4394/4885TLR2 3273/4885 |
| US-20260109696-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | KRAS, MYC, NRAS | KMT2A 1898/4885EPHX2 4152/4885TLR2 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.